In combinationwith molecular docking and molecular dynamics simulations, a new inhibitionmechanism was proposed: like a “molecular clip”, IPP1could noncovalently bind and fix a tau polypeptide chain at a multipointto prevent the transition from the “natively unfolded conformation”to the “aggregation competent conformation” before nucleation.At the cellular and animal levels, the effectiveness of the inhibitorof the IPP1 has been confirmed, providing an innovative design strategyas well as a lead compound for Alzheimer’s disease drug development. This evidence concerns the gene MAPT and Alzheimer disease.